Terns Pharmaceuticals Selected for Oral Presentation at European Hematology Association Congress For Preclinical Data on Novel Allosteric BCR-ABL Inhibitor TERN-701

Preclinical data highlight improved potency vs. asciminib across multiple clinically relevant variants of BCR-ABL including difficult-to-treat resistance mutations Early dose-escalation data from Phase 1 CARDINAL study of TERN-701 in CML patients showed compelling molecular responses in patients with heavily pre-treated CML, including deepening responses in patients with poor response to asciminib Additional safety and efficacy data from CARDINAL, including 6-month major molecular response (MMR) rates expec ...